

1 **Integrative transcriptome analysis of malignant pleural mesothelioma reveals a**
2 **clinically relevant immune-based classification**

3 Ania Alay^{1,2}, David Cordero^{1,2,3}, Sara Hijazo-Pechero^{1,2}, Elisabet Aliagas², Adriana
4 Lopez-Doriga^{1,2,3}, Raúl Marín^{1,2}, Ramón Palmero^{2,4}, Roger Llatjós⁵, Ignacio
5 Escobar⁶, Ricard Ramos⁶, Susana Padrones⁷, Víctor Moreno^{2,3,8}, Ernest Nadal^{2,4,*},
6 Xavier Solé^{1,2,3,*}

7 * Joint senior authors

8 ¹ Unit of Bioinformatics for Precision Oncology, Catalan Institute of Oncology (ICO),
9 L'Hospitalet de Llobregat, Barcelona, Spain.

10 ² Molecular Mechanisms and Experimental Therapy in Oncology Program
11 (Oncobell), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de
12 Llobregat, Barcelona, Spain.

13 ³ CIBER (Consortio de Investigación Biomédica en Red) Epidemiología y Salud
14 Pública (CIBERESP), Madrid, Spain.

15 ⁴ Thoracic Oncology Unit, Department of Medical Oncology, Catalan Institute of
16 Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain.

17 ⁵ Department of Pathology. Hospital Universitari de Bellvitge, Bellvitge Biomedical
18 Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

19 ⁶ Department of Thoracic Surgery. Hospital Universitari de Bellvitge, Bellvitge
20 Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona,
21 Spain.

22 ⁷ Department of Respiratory Medicine. Hospital Universitari de Bellvitge, Bellvitge
23 Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona,
24 Spain.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 ⁸ Oncology Data Analytics Program, Catalan Institute of Oncology (ICO) and
26 Department of Clinical Sciences, Faculty of Medicine, University of Barcelona,
27 L'Hospitalet de Llobregat, Barcelona, Spain.

28

29 Corresponding authors:

30 Xavier Solé. Unit of Bioinformatics for Precision Oncology, Oncology Data Analytics
31 Program, Catalan Institute of Oncology (ICO). Granvia de l'Hospitalet 199-203 (2nd
32 floor), 08908 L'Hospitalet de Llobregat (Barcelona), Spain; E-mail:
33 x.sole@iconcologia.net

34

35 Ernest Nadal. Thoracic Oncology Unit, Department of Medical Oncology, Catalan
36 Institute of Oncology (ICO). Granvia de l'Hospitalet 199-203 (2nd floor), 08908
37 L'Hospitalet de Llobregat (Barcelona), Spain; E-mail: esnadal@iconcologia.net

38

39 Keywords: Lung Neoplasms; Gene Expression Profiling; Tumor Microenvironment;
40 Computational Biology; Tumor Biomarkers

41 Abstract

42 **Background.** Malignant pleural mesothelioma (MPM) is a rare and aggressive
43 neoplasia affecting the lung mesothelium. Immune checkpoint inhibitors (ICI) in MPM
44 have not been extremely successful, likely due to poor identification of suitable
45 candidate patients for the therapy. We aimed to identify cellular immune fractions
46 associated with clinical outcome and classify MPM patients based on their immune
47 contexture. For each defined group, we sought for molecular specificities that could
48 help further define our MPM classification at the genomic and transcriptomic level, as
49 well as identify differential therapeutic strategies based on transcriptional signatures
50 predictive of drug response.

51 **Methods.** The abundance of 20 immune cell fractions in 516 MPM samples from 7
52 gene expression datasets was inferred using Gene Set Variation Analysis.
53 Identification of clinically relevant fractions was performed with Cox Proportional-
54 Hazards Models adjusted for age, stage, sex, and tumor histology. Immune-based
55 groups were identified using unsupervised classification.

56 **Results.** T-Helper 2 (T_{H2}) and cytotoxic T (T_C) cells were found to be consistently
57 associated with overall survival. Three immune clusters (IG) were subsequently
58 defined based on T_{H2} and T_C immune infiltration levels: IG1 (54.5%) was
59 characterized by high T_{H2} and low T_C levels, IG2 (37%) had either low or high levels
60 of both fractions, and IG3 (8.5%) was defined by low T_{H2} and high T_C levels. IG1 and
61 IG3 groups were associated with worse and better overall survival, respectively. The
62 three groups showed differential molecular profiles, with IG1 enriched for *CDKN2A*
63 and IFN-related genes deletions. At the transcriptional level, IG1 samples showed
64 upregulation of proliferation signatures, while IG3 samples presented upregulation of
65 immune and inflammation-related pathways. Finally, the integration of gene

66 expression with functional signatures of drug response showed that IG3 patients
67 might be more likely to respond to ICI, while IG1 patients could be more sensitive to
68 PARP inhibitors.

69 **Conclusions.** This study identifies a novel immune-based signature with potential
70 clinical relevance based on T_{H2} and T_C levels, unveiling a fraction of MPM patients
71 with better prognosis and who might benefit from immune-based therapies. Genomic
72 and transcriptomic specificities of the different groups could be used to tailor
73 potential therapies in the future.

74

75 Main text

76 **BACKGROUND**

77 Malignant pleural mesothelioma (MPM) is a rare and highly aggressive neoplasia
78 arising in the pleural cavity, and its incidence is increasing worldwide. MPM tumors
79 are classified into three distinct histological subtypes: epithelioid, biphasic, and
80 sarcomatoid. Median overall survival in MPM patients is approximately 12 months,
81 although patients with epithelioid tumors usually have better prognosis than
82 individuals with biphasic or sarcomatoid MPM.[1] Furthermore, most patients are
83 diagnosed in advanced stages, which still aggravates the burden caused by the
84 disease. The use of surgery in MPM patients is very limited, and current standard of
85 care treatment for MPM patients is chemotherapy with platinum combined with
86 pemetrexed, which has been shown to improve overall survival and quality of life.[2]
87 However, benefits from chemotherapy are generally modest and prognosis remains
88 dismal with 5-year survival rates lower than 5%.[3] Furthermore, there is no standard
89 second line treatment when tumor progresses to front-line chemotherapy.

90

91 Immunotherapy based on monoclonal antibodies against programmed cell death
92 protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have been tested in
93 clinical trials in MPM. Several nonrandomized phase I/II trials testing single-agent
94 immune checkpoint inhibitors showed antitumor activity (9-29%) and median
95 progression-free survival ranging from 2.8 to 6.2 months.[4] Preliminary results from
96 phase II clinical trials combining in second line inhibitors of cytotoxic T-lymphocyte-
97 associated antigen 4 (CTLA4) plus anti-PD1/PD-L1, such as ipilimumab and
98 nivolumab or tremelimumab and durvalumab, showed promising efficacy results and
99 also significant toxicity.[5] In those clinical trials, PD-L1 expression had limited value
100 to predict benefit from immune checkpoint inhibitors. Moreover, tumor mutational
101 burden (TMB) which is generally low in MPM[6] is not likely to become a predictive
102 marker in this tumor. Therefore, it is essential to further study the role of the different
103 components of the immune system in the evolution and prognosis of MPM, as well
104 as the identification of additional biomarkers of immunotherapy response beyond
105 PD-L1 immuno-histochemical expression.

106

107 In this study, our aim is to capture the landscape of the immune microenvironment in
108 a large collection of 516 MPM gene expression profiles comprised in seven different
109 publicly available datasets.[6–12] Once the immune contexture is determined for
110 every tumor, we will identify those immune cell fractions with potential prognostic
111 ability and classify MPM samples based on these previously identified clinically-
112 relevant immune cell types. We will subsequently use the defined MPM groups to
113 identify genomic and transcriptomic group specificities and evaluate functional
114 signatures of drug response to suggest possible therapeutic strategies.

115

116 **METHODS**

117 **Data collection and processing**

118 A systematic search to identify publicly available datasets was performed in January
119 2018 using the query “pleural mesothelioma” and filtering to keep only human
120 samples and expression profiling experiments in multiple open access repositories.
121 We also filtered datasets with less than 30 samples and kept experiments that
122 covered most of the transcriptome. Raw data were downloaded whenever possible
123 and subsequently processed accordingly as summarized hereafter: for whole-exome
124 sequencing data, Broad’s Genome Analysis Toolkit best practices were followed,[13]
125 RNA-sequencing data was processed according to an in-house pipeline based on
126 ENCODE best practices, and for expression arrays, robust multiarray average
127 algorithm[14] was used to normalize the data. A detailed description of data
128 identification and data processing is available in extended methods.

129

130 **Association of immune fractions with overall survival**

131 The immune infiltrate composition of 20 different cell types was deconvoluted from
132 the obtained gene expression profiles using Gene Set Variation Analysis (GSVA)
133 method.[15] Gene signatures of the different immune fractions were obtained from a
134 previous study[16] in which signatures for a total of 28 different immune cell types
135 were generated, including innate immune cells (e.g., dendritic cells, eosinophils,
136 mast cells, macrophages, natural killer cells, neutrophils) and adaptive immune cells
137 (e.g., B cells, T cells). Since GSVA can only deconvolute multi-gene signatures, we
138 replaced two single-gene signatures (plasmacytoid dendritic cells and regulatory T
139 cells) with their corresponding multi-gene signatures from another study.[17]
140 Additionally, when more specific categories were available for a cellular fraction (e.g.

141 NK CD56dim and NK CD56bright), general categories (e.g. NK cells) were removed
142 to avoid signature redundancy.

143

144 Once relative abundances for each immune fraction and sample were obtained,
145 Cox proportional-hazards models adjusted for sex, stage, age, and histology were
146 fitted using the largest dataset with available survival information as the discovery
147 dataset,[6] and setting the optimal cut point that maximized survival differences for
148 each immune fraction using R packages *survival* (v.3.1.7) and *survMisc* (v.0.5.5).
149 Using the GSVA cut points defined in the discovery dataset, Cox proportional-
150 hazards models adjusted for age, stage, sex, and histology were fitted in two
151 additional validation datasets.[7,10] Fractions associated to clinical outcome were
152 determined as those significant ($p < 0.05$) after FDR adjustment in the discovery
153 dataset and at least one validation dataset, and with a consistent hazard ratio across
154 the three datasets.

155

156 **Group characterization**

157 *Clinicopathological variables*

158 Association with clinicopathological variables (age, sex, stage, tumor histology,
159 asbestos exposure, and neoadjuvant therapy) was done using *compareGroups*
160 package for R (v.4.2.0). For categorical variables, a Chi-squared test was performed,
161 and continuous variables were tested using Kruskal-Wallis test.

162

163 *Immune checkpoints and T cell exhaustion status*

164 To assess immune checkpoints status and T cell exhaustion status in the different
165 immune groups, multiple sets of genes were obtained from previous studies,

166 including lists of immune checkpoint activators, immune checkpoint inhibitors,[18]
167 and T cell exhaustion and effector markers.[19] For each gene, we performed a
168 linear model adjusted for sex, age, stage, and histology in each dataset, where the
169 immune group was codified as a numeric variable and the gene expression was the
170 dependent variable. Datasets with less than three samples in any immune group
171 were discarded. The weighted Z method from the *survcomp* package (v.1.36.0) was
172 used to combine the p-values obtained for the different datasets. Bonferroni adjusted
173 p-values lower than 0.05 were considered as significant. β values were combined
174 using the weighted mean.

175

176 *Genomic alterations*

177 Both Bueno et al. and Hmeljak et al. datasets had somatic variant data available to
178 evaluate the mutational burden. The total number of variants per sample was
179 calculated excluding non-exonic and synonymous mutations. Using somatic single
180 nucleotide variants, mutational signatures were inferred using the R package
181 *deconstructSigs* (v.1.8.0). Neoepitope binding affinity was also derived from somatic
182 single nucleotide variants. More details on these analyses are available in extended
183 methods.

184 Copy number alteration burden was evaluated in the samples from the Hmeljak et al.
185 dataset. Fisher tests were computed to assess the differences between immune
186 groups in terms of number of altered/lost/gained genes. R package *copynumber*
187 (v.1.24.0) was used to plot the genome overview of altered samples.

188

189 *Transcriptomic analysis*

190 The association of the expression levels of individual genes with the immune groups
191 was done as described in the immune checkpoint evaluation section. For pathway
192 analysis, a pre-ranked Gene Set Enrichment Analysis (GSEA) was run with genes
193 ranked using the product of the slope and the negative $\log_{10}(\text{p-value})$ from the linear
194 model used to assess transcriptomic status at the single-gene level. Gene sets
195 tested included hallmarks and canonical pathways (KEGG, Biocarta, Reactome)
196 from MSigDB version 6.1.[20]

197

198 *Assessment of response to therapy*

199 Transcriptional signatures of sensitivity or resistance to specific treatments were
200 used to compute GSVA scores for each sample. The tested signatures were:
201 pemetrexed resistance,[21] cisplatin resistance,[22] PARP inhibitors sensitivity,[23]
202 and palbociclib resistance,[24] as well as multiple signatures predictive of benefit to
203 immunotherapy found after a systematic search literature. A total of seven previously
204 published studies with publicly available transcriptomic signatures were found.[25–
205 31] Signatures with less than 10 genes were filtered out and linear models were
206 fitted to obtain the slope of the signature correlation with the immune groups.
207 Analysis of variance was used to test for significance of the models adjusted for
208 histology and dataset.

209

210 **RESULTS**

211 **Profiling of immune fractions in a large cohort of MPM tumors leads to** 212 **clinically relevant immune cell populations**

213 In order to identify clinically relevant immune-cell fractions in MPM tumors, we
214 collected data from seven MPM gene expression datasets that fulfilled our selection


215 criteria.[6–12] Overall, we collected 516 MPM gene expression profiles, with
216 available survival information and covariates for 300 patients (58%). A summary of
217 the clinicopathological characteristics of the samples in each dataset is available in
218 Suppl. Table S1.

219 For each sample included in the analysis, we quantified the abundance of 20
220 immune-cell populations by applying GSVA[15] on a previously established set of
221 immune-specific gene signatures (Suppl. Table S2).[16,17] Thus, for each sample
222 and immune cellular fraction, we obtained a score between [-1, +1], with extreme
223 values close to 1 or -1 indicating a strong presence or absence of a fraction in a
224 specific sample, respectively. Similarly, GSVA scores close to 0 correspond to an
225 unbiased distribution (i.e., centered or randomly distributed) of the genes across the
226 whole gene expression profile.

227 Once the abundance of all immune fractions was quantified in the full cohort of
228 samples, we aimed to assess whether there existed any individual fractions
229 associated with overall patient survival using Cox proportional-hazards regression
230 models adjusted for potential confounders (i.e., age, sex, tumor stage, histology, and
231 dataset). Thus, for each cell type we identified the cut point that maximized the
232 survival differences between high vs. low using the largest available dataset (Bueno
233 et al.[6]). The cut points obtained in the discovery dataset were further validated in
234 the two additional cohorts with available survival information (Hmeljak et al.[7] and
235 Bott et al.[10]). Out of the 20 studied immune cell types, T helper 2 (T_{H2}) and
236 cytotoxic T cells (T_C) showed a consistent association with patient survival across
237 datasets based on our criteria (Cox $p < 0.05$ in at least 2 of the three datasets, and
238 the remaining dataset showing a consistent trend, albeit not necessarily significant).
239 In our analysis, higher levels of T_{H2} cells (GSVA score > -0.16) were associated with

240 worse outcome ($HR_{Bueno}=2.1$, $p=0.00015$; $HR_{Hmeljak}=2.6$, $p=0.0021$; $HR_{Bott}=2.3$,
241 $p=0.066$; $HR_{Combined}=2.1$, $p=7.6 \cdot 10^{-7}$) (Fig. 1A), while higher levels of T_C (GSVA score
242 > 0.40) were associated with better prognosis ($HR_{Bueno}=0.57$, $p=0.0091$;
243 $HR_{Hmeljak}=0.73$, $p=0.39$; $HR_{Bott}=0.29$, $p=0.016$; $HR_{Combined}=0.59$, $p=0.00094$) (Fig. 1B).
244 Survival analysis results for the complete set of immune fractions can be found in
245 Suppl. Fig. S1. When individuals were stratified in four groups based on the
246 combination of the abundance (i.e., low vs. high) of both T_{H2} and T_C cells, MPM
247 patients with low abundance of T_{H2} and high T_C infiltration consistently showed the
248 best overall survival when compared to patients with high levels of T_{H2} and low levels
249 of T_C ($HR_{Bueno}=0.34$, $p=0.00022$; $HR_{Hmeljak}=0.20$, $p=0.0080$; $HR_{Bott}=0.12$, $p=0.020$;
250 $HR_{Combined}=0.31$, $p=2.7 \cdot 10^{-7}$) (Fig. 1C). Additionally, patients with either both high or
251 low abundance levels of both cell types showed intermediate prognosis, suggesting
252 some type of compensatory effect between these two immune cell types. Therefore,
253 we decided to merge these two groups into a single category to create a final
254 classification of three immune-based groups: $T_{H2}High-T_CLow$ (IG1, worse prognosis,
255 54.5% of the patients), $T_{H2}High-T_CHigh$ or $T_{H2}Low-T_CLow$ (IG2, intermediate
256 prognosis, 37% of the patients, $HR_{Combined}=0.52$), $T_{H2}Low-T_CHigh$ (IG3, better
257 prognosis, 8.5% of the patients, $HR_{Combined}=0.32$) (Fig. 1D).

258



259


260 **Figure 1.** Overall survival by significant immune fractions.

261 Kaplan-Meier curves of T-helper 2 cells (A), cytotoxic T cells (B), the combination of both
 262 fractions in 4 groups (C), and in 3 groups (D). Hazard ratios (HR) and p-values come from a
 263 Cox proportional-hazards model adjusted for age, sex, stage, and histology.

264

265 Once the immune-based MPM groups were defined, we aimed to identify any
 266 potential differences in the remaining immune fractions among them. Groups IG1
 267 and IG2 comprised a mixture of samples with both strongly and less immune-
 268 enriched tumors, while on average group IG3 showed significant higher abundance

269 for 13 of the 20 immune cell fractions (Fig. 2A, Suppl. Fig. S2). These results
270 suggest that the combination of these two immune fractions interplays with the
271 remaining immune cell types and contributes to identify a subset of highly immune-
272 infiltrated MPM tumors with improved prognosis.



273

274 **Figure 2.** A) Relative abundances of the 20 immune fractions among 516 MPM tumours.

275 Samples are stratified in each group and clustered using Ward's method and Euclidean

276 distance. B) Volcano plot of immune checkpoints inhibitors (triangle) and activators (dot).

277 Effect size (β) correlates with immune groups: negative β values correspond to decreasing

278 expression from IG1 to IG3, while positive values indicate increasing expression from IG1 to

279 IG3. Grey-coloured dots are not significant. C) Volcano plot of T-cell exhaustion (triangle)

280 and effector (dot) markers. Effect size (β) correlates with immune groups. Grey-coloured
281 dots are not significant.

282

283 In order to explore potential additional clinical correlates of the three identified MPM
284 immune groups, we analyzed their association with available clinical covariates: age,
285 sex, tumor stage at the time of diagnosis, tumor histology, asbestos exposure, and
286 neoadjuvant therapy. Out of all the variables explored, we identified a significant
287 association with age and histology (Table 1). Patients' median age in group IG1 is 66
288 years, compared to 63.7 years and 63.2 years for groups IG2 and IG3, respectively
289 ($p=0.021$). Regarding tumor histology, IG3 showed a strong enrichment in epithelioid
290 tumors (90.70% in IG3 vs 62.04% in IG1 and 73.68% in IG2, $p=0.001$).

	N	IG1 N=281	IG2 N=191	IG3 N=44	p-value
Age, Median (Range)	385	66.00 (28.00 - 86.00)	63.70 (30.20-84.50)	63.20 (18.80-76.00)	0.021
Sex, N (%):	385				0.115
Male		166 (83.42%)	120 (81.63%)	27 (69.23%)	
Female		33 (16.58%)	27 (18.37%)	12 (30.77%)	
Stage, N (%):	348				0.888
Stage I		10 (5.32%)	9 (7.26%)	3 (8.33%)	
Stage II		33 (17.55%)	21 (16.94%)	7 (19.44%)	
Stage III		108 (57.45%)	68 (54.84%)	22 (61.11%)	
Stage IV		37 (19.68%)	26 (20.97%)	4 (11.11%)	
Histology, N (%):	507				0.001
Epithelioid		170 (62.04%)	140 (73.68%)	39 (90.70%)	
Biphasic		84 (30.66%)	39 (20.53%)	4 (9.30%)	
Sarcomatoid		20 (7.30%)	11 (5.79%)	0 (0.00%)	
Asbestos exposure, N (%):	351				0.068
No		41 (22.53%)	42 (31.82%)	15 (40.54%)	
Possible		1 (0.55%)	2 (1.52%)	1 (2.70%)	
Yes		140 (76.92%)	88 (66.67%)	21 (56.76%)	
Neoadjuvant therapy, N (%):	325				0.11
No		163 (93.68%)	101 (87.07%)	30 (85.71%)	
Yes		11 (6.32%)	15 (12.93%)	5 (14.29%)	

291 **Table 1.** Summary of clinicopathological variables by immune group.

292 To further exclude a potential confounding role of the tumor histology on the
293 differential survival among the immune groups, we evaluated whether the immune-
294 based classification still was associated with patient survival within both epithelioid
295 and non-epithelioid tumors. In epithelioid tumors, we observed improved survival in
296 IG2 and IG3 patients compared to IG1 ($HR_{IG2}=0.47$, $HR_{IG3}=0.24$, $p=3.3 \cdot 10^{-8}$) (Suppl.
297 Fig. S3A). For non-epithelioid tumors, the very small number of IG3 patients ($n=3$)
298 prevented us from obtaining reliable results for this subgroup, but we still observed a
299 trend towards better survival in IG2 patients compared to IG1 ($HR_{IG2}=0.60$, $p=0.074$)
300 (Suppl. Fig. S3B).

301

302 **Immune groups correlate with most immune checkpoint markers and markers** 303 **of effector and exhausted T cells**

304 To further evaluate the potential clinical relevance of the identified immune groups,
305 we evaluated the expression of a wide selection of immune checkpoint inhibitors and
306 activators. We observed a significant increasing expression pattern across MPM
307 immune groups for most of the evaluated checkpoint markers (Fig. 2B). *TNFRSF14*,
308 *IL2RB*, *TNFRSF18 (GITR)*, *CD27* and *ICOS* were among the strongest positively
309 associated activator markers with the immune groups. Regarding immune
310 checkpoint inhibitors, *LAG3*, *TIGIT*, *VSIR (VISTA)*, *IDO1*, *CTLA4* and *PDCD1 (PD-1)*
311 were the strongest correlated markers. In opposition, *CD276 (B7-H3)* showed
312 negative correlation with the immune groups, being its expression higher in IG1
313 tumors than tumors in IG2 and IG3 groups. Detailed expression of *CD274 (PD-L1)*,
314 *PDCD1 (PD-1)*, *CTLA4*, *CD276 (B7-H3)*, and *VSIR (VISTA)* in each dataset is
315 available in Suppl. Fig. S4A, showing the distribution of tumors in each group. An
316 overall higher expression of *VSIR* with respect to the other immune checkpoints is

317 observed, as previously reported in other publications. [7,32] Importantly, immune
318 groups still show significant differences in prognosis independently of the expression
319 level of any of these five immune checkpoints (Suppl. Fig. S4B). Additionally, we
320 also evaluated markers of effector and exhausted T cells correlated with the
321 identified MPM immune groups (Fig. 2C). In our analysis, all evaluated markers –
322 excluding *CD44* – showed a positive correlation with the immune group
323 classification, with a majority being significantly enriched in IG3 (*PRF1, GZB, TBX21,*
324 *EOMES, PDCD1*).


325

326 **Genomic characterization reveals IG1 tumors present more genomic instability**

327 Once we identified the different immune-based groups in MPM tumors and
328 established their potential clinical relevance, we wanted to characterize the different
329 groups at the genomic level to identify any potential differential genomic patterns.
330 These analyses were performed using Bueno et al.[6] and Hmeljak et al.[7] datasets.
331 Using whole-exome data from Bueno et al.[6] and Hmeljak et al.[7] datasets, we
332 assessed if immune groups were different in terms of TMB, mutational
333 signatures,[33] or antigen immunogenicity (Fig. 3A-C). Although we did not find
334 statistically significant differences among immune groups for any of the previous
335 analyses, we did observe a slight decrease of mutational Signature 3 in IG3 tumors
336 compared to IG1 and IG2 patients. Signature 3 is associated with homologous
337 recombination deficiency and *BRCA1/2* deficiency.[33] Additionally, at the single-
338 gene level no gene was found to be preferentially mutated in any group (data not
339 shown).

340 Copy number alterations were assessed for Hmeljak et al. dataset.[7] There were no
341 significant differences between immune groups in the overall number of altered

342 genes per sample, although tumors in IG3 tend to have fewer copy number
343 alterations overall compared to the other groups as shown in Figure 3D. Figure 3E
344 shows the overall percentage of altered samples across the genome for each
345 immune group. Regarding MPM landmark genes, genes like *BAP1*, *SETD2*, *LATS2*,
346 *TP53* and *NF2* did not show differences between groups. *CDKN2A* however is
347 altered in 81% of tumors in IG1, in 47% of tumors in IG2, and 14% of tumors in IG3.
348 Suppl. Fig. S5 shows expression of frequent tumor suppressor genes inactivated in
349 MPM,[3] and results correlate with genomics, as *CDKN2A* expression is strongly
350 correlated with immune groups in the largest datasets.



351

352 **Figure 3.** Genomic characterization

353 A) Tumour mutational burden among immune groups. Mean number of variants per sample.

354 Error bars indicate SD. B) Distribution of COSMIC mutational signatures among each

355 immune group. C) Immunogenicity as the mean of IC50 affinity of mutations among immune

356 groups. D) Copy number burden among immune groups. Mean number of altered genes

357 per sample. Error bars indicate SD. Lighter colours show copy number gains while darker
358 ones depict copy number losses. E) Genomic overview showing the percentage of samples
359 with copy number alterations among each immune group. Landmark MPM genes are
360 depicted according to their genomic location.

361


362 **Transcriptional cell cycle / immune system activity trade-off across immune** 363 **groups**

364 Next, we sought for gene expression differences among the three immune groups, to
365 identify those genes with an increasing or decreasing pattern among the three
366 groups. The results are depicted in Fig. 4A, which shows a high number of genes
367 with decreasing expression from IG1 to IG3 tumors related to cell proliferation such
368 as *CENPF* (centromere protein also known as mitosin), *BIRC5* (otherwise known as
369 survivin, preventing apoptotic cell death), or kinesins like *KIF23*, involved in cell
370 division. On the other hand, genes positively correlated with the immune groups
371 include immune system related genes such as *HSH2D*, a target of T-cell activation
372 signaling pathways, and *GNLY*, which encodes for a protein present in cytotoxic
373 granules of cytotoxic T lymphocytes.

374 In order to capture more precisely the enriched pathways and biological functions of
375 the genes identified in the previous analysis, we performed a pre-ranked GSEA
376 using a set of transcriptional signatures covering a wide range of pathways, and the
377 genes ranked according to their linear association with the immune groups. The
378 results are shown in Fig. 4B and we observed that signatures more positively
379 correlated with the immune group (i.e., more expressed in IG3 tumors) were mostly
380 related to immune system and inflammatory response processes. Contrarily,
381 signatures negatively correlated with the immune groups mostly relate to cell cycle

382 and epithelial mesenchymal transition, suggesting a trade-off between these
383 molecular processes and the immune system.

384 Finally, since IG1 tumors appeared to be driven by cell cycle deregulation, we
385 assessed the potential confounder effect among cell proliferation and immune
386 groups. Therefore, we tested the association between the cell proliferation marker
387 *MKI67* and the immune groups. Notably, regardless of *MKI67* expression levels, the
388 association of the improving survival pattern across immune groups is upheld (Suppl.
389 Fig. S6).



390

391 **Figure 4.** Transcriptomic characterization

392 A) Volcano plot of gene expression. Effect size (β) correlates with immune groups. B)

393 Significant pathways from pre-ranked GSEA. Positive normalized enrichment scores

394 correlate with an increasing expression of pathway from IG1 to IG3, while negative ones

395 depict higher pathway expression for IG1 tumours vs. IG3 tumours. Pathways are clustered

396 using Ward's method and an odds-ratio based distance.


397 **Potential therapeutic strategies**

398 To further evaluate the potential clinical benefit of the immune-based MPM
399 classification, we decided to assess the behavior of different treatment-response
400 signatures among the three groups. We first wanted to identify whether there were
401 any differences in the response to the currently available standard chemotherapy
402 treatment based on the combination of cisplatin and pemetrexed. We obtained two
403 expression-based signatures derived from non-small cell lung cancer that predicted
404 resistance to pemetrexed[21] and to cisplatin.[22] Figure 5A displays GSVA scores
405 for the two signatures across the three MPM immune groups. Overall, the results of
406 the analysis suggested that MPM tumors in IG1 might be more resistant to
407 pemetrexed, while IG3 tumors show a trend to lower resistance. On the other hand,
408 cisplatin resistance analysis showed no differences between immune groups.

409 Next, we tested a large set of gene-expression signatures predictive of benefit from
410 ICI treatment[25–31] to formally evaluate if MPM tumors in IG3 could benefit from an
411 immune-based therapeutic approach (Fig. 5B). The overlap between these
412 signatures and the classifier is almost non-existent (3 shared genes at most). We
413 observed that all signatures were positively correlated with the immune groups, with
414 IG3 tumors presenting a significant upregulation for all but one of the signatures.

415 Given the increased activation of cell cycle and DNA repair processes in the IG1
416 group of MPM tumors, we wanted to explore whether any differences in sensitivity to
417 cyclin dependent kinase inhibitors and to drugs that inhibit DNA repair among the
418 three groups. To do that, we collected a signature of resistance to palbociclib derived
419 from breast cancer[24] and another computationally-derived signature predicting
420 sensitivity to DNA repair inhibition with PARP inhibitors.[23] (Fig. 5C). Despite a
421 higher cycling nature of tumors in group IG1, they appear to be more resistant to

422 palbociclib than tumors in other groups, based on this predictive signature. Strikingly,
423 tumors in IG1 showed increased sensitivity to PARP inhibitors compared to the other
424 groups.



425
426 **Figure 5.** Assessment of gene expression signatures predictive of benefit or resistance to
427 multiple treatments.

428 GSVAscore for each sample allowed to test resistance to first-line chemotherapy (A);
429 response to immunotherapy (B), and resistance or sensitivity to targeted therapy (C).

430 Superscripts in immunotherapy signatures correspond to bibliographic references. Up-reg.:
431 up-regulated; down-reg.: down-regulated.

432

433 **DISCUSSION**

434 In this study we performed a comprehensive analysis of publicly available
435 transcriptome data from more than 500 MPM tumors in order to characterize the
436 immune landscape of this disease. By the identification of immune cells associated
437 with clinical outcome, we classified MPM tumors according to their T-helper 2 and
438 cytotoxic T cell abundance levels. This classification stratifies patients into three
439 groups that represent different immune infiltration patterns and are associated with
440 distinct survival outcomes. The group with the shortest overall survival, IG1,
441 represents more than 50% of the analyzed tumors, while IG3, with better prognosis,
442 accounts for only 8.5% of the tumors. We observed an increasing pattern of
443 abundance for most immune fractions across the three immune groups. Interestingly,
444 the survival benefit of this classification is consistent in both epithelioid and non-
445 epithelioid tumors. We further characterized these three MPM immune groups at the
446 genomic and transcriptomic levels, and identified potential therapeutic strategies
447 using predictive signatures and large-scale pharmacogenomics data.

448 Different immune-related MPM phenotypes have already been described in recent
449 studies using comprehensive approaches.[34–38] These studies use different
450 techniques such as Nanostring™ technology,[35] mass cytometry,[34] or RNA-
451 sequencing.[37] The diversity of obtained results suggests that the composition and
452 role of the tumor microenvironment in MPM is remarkably complex and controversial,
453 and thus further studies will contribute to elucidate this question.

454 In our work, MPM tumors are classified based on T_{H2} and T_C cells abundance, as
455 previously stated. T_{H2} are CD4⁺ T cells which are induced by the presence of
456 interleukin 4 (IL4) via STAT6 signaling and regulate humoral immune responses and
457 responses to extracellular pathogens. T_{H2} cells secrete IL4, IL5, IL10 and IL13 which
458 promote immune suppression by inhibiting T-Helper 1 cytokine production.
459 Additionally, a recent study identified higher levels of IL5 and IL13 after exposure to
460 asbestos in mesothelial cells.[39] The role of T_{H2} cells in cancer has been found to
461 be dual and context-dependent. While they can generate antitumor immunity by
462 recruiting specific populations of innate immune cells, they have also been found to
463 increase tumorigenicity in certain experimental models.[40] Consistent with our
464 results, higher levels of T_{H2} cells have already been associated with poor prognosis
465 in multiple cancer types.[41–43] Finally, in the analysis performed by Hmeljak et
466 al.,[7] this signature has already been associated to the group with the worst
467 prognosis.

468 On the other hand, CD8⁺ T_C cells are essential actors of the effector function of
469 adaptive cellular immune response.[44] Along with natural killer (NK) cells, T_C cells
470 are ultimately responsible for targeting and attacking cancer cells by secreting
471 cytotoxins (e.g., granzymes and perforins) which reach the tumor cell cytoplasm and
472 trigger a caspase-mediated apoptotic process.[45] Additionally, in agreement with
473 our study, a recent pan-cancer study observed that patients with tumors with higher
474 T_C infiltration tended to have better survival than patients with less T_C-infiltrated
475 tumors.[46]

476 While most immune checkpoints correlate with the defined immune groups, *CD276*
477 (*B7-H3*) shows an opposite pattern of expression, with decreasing expression from
478 IG1 to IG3. *CD276* is a member of the B7 family of immunoregulatory proteins and is

479 overexpressed in distinct tumor types. It has been shown that *CD276* can promote
480 tumor proliferation, angiogenesis and metastasis and is associated with shorter
481 survival time.[47] This result ties in with the survival pattern among the groups as
482 well as with results from functional analysis in which cell cycle shows a decreasing
483 pattern from IG1 to IG3. Similarly, *CD44* is the only T-cell exhaustion marker that
484 shows negative correlation with the immune groups. This marker has been
485 associated with metastasis and low survival rate in multiple cancer types, and
486 chemoresistance in prostate and head and neck squamous cell cancer types.[48] In
487 MPM, *CD44* has been shown to promote invasiveness when interacting with
488 hyaluronan.[49]

489 Regarding molecular characteristics, immune groups were not significantly
490 correlated with specific genomic alterations in terms of gene mutations or copy
491 number alterations, yet there seems to be a pattern of decreasing genomic instability
492 among the groups. Genomic instability, higher in IG1, is also supported by the
493 analysis of mutational signatures, revealing a possible stronger presence of DNA
494 damage repair deficiency by means of homologous recombination repair. In terms of
495 copy number, no global differences were found among MPM groups, possibly due to
496 the smaller sample size (only one dataset with available data). However, genomic
497 regions like 9p21, harboring landmark genes in MPM as *CDKN2A* or type I interferon
498 gene cluster, were likely to be lost in the IG1 compared to the other two groups.

499 Transcriptomic characterization of these groups by gene enrichment analysis
500 revealed a trade-off between immune response activity and cell proliferation
501 mechanisms, showing higher activation of cell cycle in IG1 tumors, in agreement with
502 genomic characteristics. This trade-off has already been described in other studies,

503 reinforcing the hypothesis that cell cycle regulators and genomic instability could also
504 have an impact on immune checkpoints.[46,50]
505 Finally, the lack of effective therapeutic strategies beyond chemotherapy in MPM
506 calls for assessment of potential options and tailoring for each subset of patients.
507 Currently several phase III clinical trials are assessing the role of ICI in combination
508 with chemotherapy in the first line setting of patients with advanced MPM. The
509 results of the CheckMate-743 trial evaluating nivolumab plus ipilimumab versus
510 platinum-based chemotherapy in previously untreated MPM are eagerly awaited,
511 since this trial met its primary endpoint of overall survival. In this sense, the
512 treatment landscape of advanced MPM is likely to evolve and predictive markers of
513 ICI benefit are needed. In our work, we observed that patients belonging to IG3 may
514 benefit from pemetrexed and immunotherapy, while no group showed any strong
515 predisposition to benefit from chemotherapy with cisplatin treatment. Moreover,
516 tumors in IG1 appear to be more sensitive to PARP inhibitors. This coincides with a
517 higher proportion of genomic instability and mutational signature 3, associated with
518 BRCA deficiency. It is important to stress that this classification needs further
519 validation in a prospective cohort to identify the most suitable therapeutic strategy for
520 patients in each immune group. It is also important to point out that this study
521 focused on gene expression signatures as proxies since there is no information
522 regarding immunotherapy in large pharmaco-genomic assays and also that even
523 though pemetrexed and cisplatin are commonly administered in combination; we
524 assessed their effect as single therapies due to the lack of signatures for the
525 combined treatment.
526 To sum up, this study identifies a novel signature with potential clinical relevance
527 based on T_{H2} and T_C levels and unveils a small fraction of MPM tumors that show

528 better prognosis. These groups have different characteristics, both at the genomic
529 and transcriptomic levels, and these differences could be used to tailor potential
530 therapies for each group in the future. Further research is needed towards the
531 identification of a reduced signature valid for FFPE samples, and validation of these
532 results is warranted in an independent and prospective cohort of MPM tumors
533 preferentially treated with ICI.

534

535 Declarations

536 *Acknowledgements*

537 We thank CERCA Programme / Generalitat de Catalunya for institutional support.

538 We thank all the researchers who kindly put their research data for public use.

539 Bueno et al. data was accessed through a data transfer agreement with Genentech

540 (DAT-015429).

541 *Funding*

542 This work is supported by the Carlos III National Health Institute funded by FEDER

543 funds – a way to build Europe – [PI14/01109; PI18/00920]; the Government of

544 Catalonia [2017SGR448].

545 XS is supported by RTI2018-102134-A-I00 grant funded by Spanish Ministry of

546 Science and Innovation. EN received support from the SLT006/17/00127 grant,

547 funded by the Department of Health of the Generalitat de Catalunya by the call

548 “Acció instrumental d’intensificació de professionals de la salut”. This study has been

549 funded by Sociedad Española de Oncología Médica (SEOM) through “Proyectos de

550 Investigación para Grupo Emergente”.

551 *Authors’ contributions*

552 XS and EN conceived and designed the study. AA and DC performed the
553 computational and statistical analysis. XS, EN, AA, DC, SHP, and EA contributed to
554 the interpretation of the results. XS, EN, AA, and DC drafted the manuscript. ALD,
555 RM, RP, RL, IE, RR, SP, and VM provided critical revisions of the article. All authors
556 read and approved the final manuscript.

557 *Competing interests*

558 VM is consultant to Bioiberica S.A.U. and Grupo Ferrer S.A., received research
559 funds from Universal DX, and is coinvestigator in grants with Aniling. EN participated
560 in advisory boards from Bristol Myers Squibb, Merck Sharpe & Dohme, Lilly, Roche,
561 Pfizer, Takeda, Boehringer Ingelheim, Amgen and AstraZeneca. The other authors
562 have no conflicts of interest to declare.

563 *Ethics approval and consent to participate*

564 Not required.

565 *Data availability statement*

566 Data used in this study are available in public, open access repositories.

567

568 List of abbreviations

569 FDR: False Discovery Rate

570 GSEA: Gene Set Enrichment Analysis

571 GSVA: Gene Set Variation Analysis

572 ICI: Immune Checkpoint Inhibitors

573 MPM: Malignant Pleural Mesothelioma

574 PD1: Programmed Cell Death Protein 1

575 PD-L1: Programmed Death Ligand 1

576 T_C: Cytotoxic T cells

577 T_{H2}: T-helper 2 cells

578 TMB: Tumor Mutational Burden

579

580 **REFERENCES**

581 1 Meyerhoff RR, Yang C-FJ, Speicher PJ, *et al.* Impact of mesothelioma
582 histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results
583 database. *J Surg Res* 2015;**196**:23–32. doi:10.1016/j.jss.2015.01.043

584 2 Kindler HL, Ismaila N, Armato SG, *et al.* Treatment of Malignant Pleural
585 Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. *J*
586 *Clin Oncol* 2018;**36**:1343–73. doi:10.1200/JCO.2017.76.6394

587 3 Yap TA, Aerts JG, Popat S, *et al.* Novel insights into mesothelioma biology
588 and implications for therapy. *Nat Rev Cancer* 2017;**17**:475–88.
589 doi:10.1038/nrc.2017.42

590 4 McCambridge AJ, Napolitano A, Mansfield AS, *et al.* Progress in the
591 Management of Malignant Pleural Mesothelioma in 2017. *J Thorac Oncol*
592 2018;**13**:606–23. doi:10.1016/j.jtho.2018.02.021

593 5 Scherpereel A, Wallyn F, Albelda SM, *et al.* Novel therapies for malignant
594 pleural mesothelioma. *Lancet Oncol* 2018;**19**:e161–72. doi:10.1016/S1470-
595 2045(18)30100-1

596 6 Bueno R, Stawiski EW, Goldstein LD, *et al.* Comprehensive genomic analysis
597 of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and
598 splicing alterations. *Nat Genet* 2016;**48**:407–16. doi:10.1038/ng.3520

599 7 Hmeljak J, Sanchez-Vega F, Hoadley KA, *et al.* Integrative Molecular
600 Characterization of Malignant Pleural Mesothelioma. *Cancer Discov* 2018;**8**:1548–
601 65. doi:10.1158/2159-8290.CD-18-0804

- 602 8 Suraokar MB, Nunez MI, Diao L, *et al.* Expression profiling stratifies
603 mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and
604 microtubule network with therapeutic implications. *Ann Oncol* 2014;**25**:1184–92.
605 doi:10.1093/annonc/mdu127
- 606 9 de Reyniès A, Jaurand M-C, Renier A, *et al.* Molecular classification of
607 malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to
608 the epithelial-to-mesenchymal transition. *Clin Cancer Res* 2014;**20**:1323–34.
609 doi:10.1158/1078-0432.CCR-13-2429
- 610 10 Bott M, Brevet M, Taylor BS, *et al.* The nuclear deubiquitinase BAP1 is
611 commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural
612 mesothelioma. *Nat Genet* 2011;**43**:668–72. doi:10.1038/ng.855
- 613 11 López-Ríos F, Chuai S, Flores R, *et al.* Global gene expression profiling of
614 pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion
615 as prognostic factors and critical evaluation of microarray-based prognostic
616 prediction. *Cancer Res* 2006;**66**:2970–9. doi:10.1158/0008-5472.CAN-05-3907
- 617 12 Gordon GJ, Rockwell GN, Jensen RV, *et al.* Identification of novel candidate
618 oncogenes and tumor suppressors in malignant pleural mesothelioma using large-
619 scale transcriptional profiling. *Am J Pathol* 2005;**166**:1827–40. doi:10.1016/S0002-
620 9440(10)62492-3
- 621 13 Van der Auwera GA, Carneiro MO, Hartl C, *et al.* From FastQ data to high
622 confidence variant calls: the Genome Analysis Toolkit best practices pipeline. *Curr*
623 *Protoc Bioinformatics* 2013;**43**:11.10.1-11.10.33.
624 doi:10.1002/0471250953.bi1110s43
- 625 14 Irizarry RA, Hobbs B, Collin F, *et al.* Exploration, normalization, and
626 summaries of high density oligonucleotide array probe level data. *Biostatistics*

- 627 2003;**4**:249–64. doi:10.1093/biostatistics/4.2.249
- 628 15 Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for
629 microarray and RNA-seq data. *BMC Bioinformatics* 2013;**14**:7. doi:10.1186/1471-
630 2105-14-7
- 631 16 Bindea G, Mlecnik B, Tosolini M, *et al.* Spatiotemporal dynamics of
632 intratumoral immune cells reveal the immune landscape in human cancer. *Immunity*
633 2013;**39**:782–95. doi:10.1016/j.immuni.2013.10.003
- 634 17 Charoentong P, Finotello F, Angelova M, *et al.* Pan-cancer Immunogenomic
635 Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of
636 Response to Checkpoint Blockade. *Cell Rep* 2017;**18**:248–62.
637 doi:10.1016/j.celrep.2016.12.019
- 638 18 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy.
639 *Nat Rev Cancer* 2012;**12**:252–64. doi:10.1038/nrc3239
- 640 19 Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion.
641 *Nat Rev Immunol* 2015;**15**:486–99. doi:10.1038/nri3862
- 642 20 Subramanian A, Tamayo P, Mootha VK, *et al.* Gene set enrichment analysis:
643 a knowledge-based approach for interpreting genome-wide expression profiles. *Proc*
644 *Natl Acad Sci USA* 2005;**102**:15545–50. doi:10.1073/pnas.0506580102
- 645 21 Hou J, Lambers M, den Hamer B, *et al.* Expression profiling-based subtyping
646 identifies novel non-small cell lung cancer subgroups and implicates putative
647 resistance to pemetrexed therapy. *J Thorac Oncol* 2012;**7**:105–14.
648 doi:10.1097/JTO.0b013e3182352a45
- 649 22 Whiteside MA, Chen D-T, Desmond RA, *et al.* A novel time-course cDNA
650 microarray analysis method identifies genes associated with the development of
651 cisplatin resistance. *Oncogene* 2004;**23**:744–52. doi:10.1038/sj.onc.1207164

- 652 23 McGrail DJ, Lin CC-J, Garnett J, *et al.* Improved prediction of PARP inhibitor
653 response and identification of synergizing agents through use of a novel gene
654 expression signature generation algorithm. *NPJ Syst Biol Appl* 2017;**3**:8.
655 doi:10.1038/s41540-017-0011-6
- 656 24 Malorni L, Piazza S, Ciani Y, *et al.* A gene expression signature of
657 retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib
658 in breast cancer cell lines and is prognostic in patients with ER positive early breast
659 cancer. *Oncotarget* 2016;**7**:68012–22. doi:10.18632/oncotarget.12010
- 660 25 Lesterhuis WJ, Rinaldi C, Jones A, *et al.* Network analysis of immunotherapy-
661 induced regressing tumours identifies novel synergistic drug combinations. *Sci Rep*
662 2015;**5**:12298. doi:10.1038/srep12298
- 663 26 Hugo W, Zaretsky JM, Sun L, *et al.* Genomic and Transcriptomic Features of
664 Response to Anti-PD-1 Therapy in Metastatic Melanoma. *Cell* 2016;**165**:35–44.
665 doi:10.1016/j.cell.2016.02.065
- 666 27 Gao J, Shi LZ, Zhao H, *et al.* Loss of IFN- γ Pathway Genes in Tumor Cells as
667 a Mechanism of Resistance to Anti-CTLA-4 Therapy. *Cell* 2016;**167**:397-404.e9.
668 doi:10.1016/j.cell.2016.08.069
- 669 28 Ayers M, Lunceford J, Nebozhyn M, *et al.* IFN- γ -related mRNA profile predicts
670 clinical response to PD-1 blockade. *J Clin Invest* 2017;**127**:2930–40.
671 doi:10.1172/JCI91190
- 672 29 Chen P-L, Roh W, Reuben A, *et al.* Analysis of Immune Signatures in
673 Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and
674 Mechanisms of Resistance to Immune Checkpoint Blockade. *Cancer Discov*
675 2016;**6**:827–37. doi:10.1158/2159-8290.CD-15-1545
- 676 30 Johnson DB, Estrada MV, Salgado R, *et al.* Melanoma-specific MHC-II

- 677 expression represents a tumour-autonomous phenotype and predicts response to
678 anti-PD-1/PD-L1 therapy. *Nat Commun* 2016;**7**:10582. doi:10.1038/ncomms10582
- 679 31 Prat A, Navarro A, Paré L, *et al.* Immune-Related Gene Expression Profiling
680 After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous
681 Cell Carcinoma, and Melanoma. *Cancer Res* 2017;**77**:3540–50. doi:10.1158/0008-
682 5472.CAN-16-3556
- 683 32 Muller S, Victoria Lai W, Adusumilli PS, *et al.* V-domain Ig-containing
684 suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint
685 molecule, is highly expressed in epithelioid malignant pleural mesothelioma. *Mod*
686 *Pathol* 2020;**33**:303–11. doi:10.1038/s41379-019-0364-z
- 687 33 Alexandrov LB, Nik-Zainal S, Wedge DC, *et al.* Signatures of mutational
688 processes in human cancer. *Nature* 2013;**500**:415–21. doi:10.1038/nature12477
- 689 34 Lee H-S, Jang H-J, Choi JM, *et al.* Comprehensive immunoproteogenomic
690 analyses of malignant pleural mesothelioma. *JCI Insight* 2018;**3**.
691 doi:10.1172/jci.insight.98575
- 692 35 Patil NS, Righi L, Koeppen H, *et al.* Molecular and Histopathological
693 Characterization of the Tumor Immune Microenvironment in Advanced Stage of
694 Malignant Pleural Mesothelioma. *J Thorac Oncol* 2018;**13**:124–33.
695 doi:10.1016/j.jtho.2017.09.1968
- 696 36 Blum Y, Meiller C, Quetel L, *et al.* Dissecting heterogeneity in malignant
697 pleural mesothelioma through histo-molecular gradients for clinical applications. *Nat*
698 *Commun* 2019;**10**:1333. doi:10.1038/s41467-019-09307-6
- 699 37 Alcala N, Mangiante L, Le-Stang N, *et al.* Redefining malignant pleural
700 mesothelioma types as a continuum uncovers immune-vascular interactions.
701 *EBioMedicine* 2019;**48**:191–202. doi:10.1016/j.ebiom.2019.09.003

- 702 38 Sneddon S, Rive CM, Ma S, *et al.* Identification of a CD8+ T-cell response to
703 a predicted neoantigen in malignant mesothelioma. *Oncol Immunology*
704 2020;**9**:1684713. doi:10.1080/2162402X.2019.1684713
- 705 39 Maki Y, Nishimura Y, Toyooka S, *et al.* The proliferative effects of asbestos-
706 exposed peripheral blood mononuclear cells on mesothelial cells. *Oncol Lett*
707 2016;**11**:3308–16. doi:10.3892/ol.2016.4412
- 708 40 Liudahl SM, Coussens LM. To Help or To Harm. In: *Immunology*. Elsevier
709 2018. 97–116. doi:10.1016/B978-0-12-809819-6.00008-3
- 710 41 De Monte L, Reni M, Tassi E, *et al.* Intratumor T helper type 2 cell infiltrate
711 correlates with cancer-associated fibroblast thymic stromal lymphopoietin production
712 and reduced survival in pancreatic cancer. *J Exp Med* 2011;**208**:469–78.
713 doi:10.1084/jem.20101876
- 714 42 Kusuda T, Shigemasa K, Arihiro K, *et al.* Relative expression levels of Th1
715 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian
716 cancer. *Oncol Rep* 2005;**13**:1153–8.
- 717 43 Nevala WK, Vachon CM, Leontovich AA, *et al.* Evidence of systemic Th2-
718 driven chronic inflammation in patients with metastatic melanoma. *Clin Cancer Res*
719 2009;**15**:1931–9. doi:10.1158/1078-0432.CCR-08-1980
- 720 44 Andersen MH, Schrama D, Thor Straten P, *et al.* Cytotoxic T cells. *J Invest*
721 *Dermatol* 2006;**126**:32–41. doi:10.1038/sj.jid.5700001
- 722 45 Martínez-Lostao L, Anel A, Pardo J. How Do Cytotoxic Lymphocytes Kill
723 Cancer Cells? *Clin Cancer Res* 2015;**21**:5047–56. doi:10.1158/1078-0432.CCR-15-
724 0685
- 725 46 Tamborero D, Rubio-Perez C, Muiños F, *et al.* A Pan-cancer Landscape of
726 Interactions between Solid Tumors and Infiltrating Immune Cell Populations. *Clin*

- 727 *Cancer Res* 2018;**24**:3717–28. doi:10.1158/1078-0432.CCR-17-3509
- 728 47 Seaman S, Zhu Z, Saha S, *et al.* Eradication of Tumors through Simultaneous
729 Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. *Cancer Cell*
730 2017;**31**:501-515.e8. doi:10.1016/j.ccell.2017.03.005
- 731 48 Chen C, Zhao S, Karnad A, *et al.* The biology and role of CD44 in cancer
732 progression: therapeutic implications. *J Hematol Oncol* 2018;**11**:64.
733 doi:10.1186/s13045-018-0605-5
- 734 49 Cortes-Dericks L, Schmid RA. CD44 and its ligand hyaluronan as potential
735 biomarkers in malignant pleural mesothelioma: evidence and perspectives. *Respir*
736 *Res* 2017;**18**:58. doi:10.1186/s12931-017-0546-5
- 737 50 Wellenstein MD, de Visser KE. Cancer-Cell-Intrinsic Mechanisms Shaping the
738 Tumor Immune Landscape. *Immunity* 2018;**48**:399–416.
739 doi:10.1016/j.immuni.2018.03.004
- 740